Adler, LA, Edson, R, Lavori, P, et al. (1998) Long-term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry, 43: 868–72.
Ahmed, S, Chengappa, KN, Naidu, VR, et al. (1998) Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. Journal of Clinical Psychiatry, 59: 472–7.
Alabed, S, Latifeh, Y, Mohammad, HA, et al. (2011) Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, 4: CD000203 (doi: 10.1002/14651858.CD000203.pub3).
Anderson, KE, Stamler, D, David, MD, et al. (2017) Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Psychiatry, 4: 595–604.
Arbuthnott, G, Garcia-Munoz, M (2010) Neuropharmacology. In Companion to Psychiatric Studies (eds Johnstone, EC, Owens, DGC, Lawrie, SM, et al. ): 45–76. Churchill Livingstone.
Bergman, H, Walker, D-M, Nikolakopoulou, A, et al. (2017) Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technology Assessment, 21(43): 1–218.
Bergman, H, Rathbone, J, Agarwal, V, et al. (2018) Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews, 2: CD000459 (doi: 10.1002/14651858.CD000459.pub3).
Bhidayasiri, R, Jitkritsadakul, O, Friedman, JH, et al. (2018) Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. Journal of Neurological Sciences, 389: 67–75.
Bishnoi, M, Chopra, K, Kilkarni, SK (2007) Protective effect of rutin, a polyphenolic flavinoid, against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundamental Clinical Pharmacology, 21: 521–9.
Cadet, JL, Lohr, JB, Jeste, DV (1986) Free radicals and tardive dyskinesia. Trends in Neurosciences, 9: 107–8.
Calabresi, P, Pisani, A, Rothwell, J, et al. (2016) Hyperkinetic disorders and loss of synaptic downscaling. Nature Neuroscience, 19: 868–75.
Carbon, M, Hsieh, C-H, Kane, JM, et al. (2017) Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. Journal of Clinical Psychiatry, 78: e264–78.
Caroff, SN, Walker, P, Campbell, C, et al. (2007) Treatment of tardive dyskinesia with galantamine: a randomised controlled cross-over trial. Journal of Clinical Psychiatry, 68: 410–5.
Citrome, L, Jaffe, A, Levine, J, et al. (2005) Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Journal of Clinical Psychiatry, 66: 1512–6.
Citrome, L, Kantrowitz, JT (2009) Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Reviews in Neurotherapy, 9: 1045–58.
Citrome, L (2017a) Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 71: e12964.
Citrome, L (2017b) Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 71: e13030.
Davis, MC, Miller, BJ, Kalsi, JK, et al. (2017) Efficient trial design – FDA approval of valbenazine for tardive dyskinesia. New England Journal of Medicine, 376: 2503–6.
Elkashef, AM, Wyatt, RJ (1999) Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophrenia Bulletin, 25: 731–40.
Fernandez, HH, Factor, SA, Hauser, RA, et al. (2017) Randomised controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology, 88: 2003–10.
Fibiger, HC, Lloyd, KG (1984) Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends in Neurosciences, 7: 462–4.
Fischer-Barnicol, D, Lanquillon, S, Haen, E, et al. (2008) Typical and atypical antipsychotics – the misleading dichotomy. Neuropsychobiology, 57: 80–7.
Gerlach, J (1981) Prevention/treatment of tardive dyskinesia. Acta Psychiatrica Scandinavica Supplementum, 291: 117–28.
Grigoriadis, DE, Smith, E, Hoare, SR, et al. (2017) Pharmacologic characterisation of valbenazine (NBI-98854) and its metabolites. Journal of Pharmacology and Experimental Therapeutics, 361: 454–61.
Guay, DRP (2010) Tetrabenzine: a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. American Journal of Geriatric Pharmacotherapy, 8: 331–72.
Guy, W (1976) ECDEU Assessment Manual for Psychopharmacology (publication ADM 76 – 338). US Department of Health, Education and Welfare.
Hatcher-Martin, JM, Armstrong, KA, Scorr, LM, et al. (2016) Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism and Related Disorders, 32: 124–6.
Hauser, RA, Factor, SA, Marder, SR, et al. (2017) KINECT 3: a Phase 3 randomised, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry, 174: 476–84.
Hazari, N, Kate, N, Grover, S (2013) Clozapine and tardive movement disorders: a review. Asian Journal of Psychiatry, 6: 439–51.
Howes, OD, Kapur, S (2009) The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophrenia Bulletin, 35: 549–62.
Jankovic, J (2009) Treatment of hyperkinetic movement disorders. Lancet Neurology, 8: 844–56.
Jankovic, J (2017) An update on new and unique uses of botulinum toxin in movement disorders. Toxicon, 147: 84–8.
Jeste, DV, Wyatt, RJ (1981) Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity? Journal of Clinical Psychiatry, 42: 455–7.
Jeste, DV, Lohr, JB, Clark, K, et al. (1988) Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology, 8(suppl 4): 38S–48S.
Jones, PB, Barnes, TR, Davies, L, et al. (2006) Randomised controlled trial of the effect on Quality of Life of second- versus first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry, 63: 1079–87.
Karson, CN, Jeste, DV, LeWitt, PA, et al. (1983) A comparison of two iatrogenic dyskinesias. American Journal of Psychiatry, 140: 1504–6.
Li, YC, Kavalali, ET (2017) Synaptic vesicle-recycling machinery components as potential therapeutic targets. Pharmacological Reviews, 69: 141–60.
Lieberman, JA, Salz, BL, Johns, CA, et al. (1991) The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158: 503–10.
Lieberman, JA, Stroup, TS, McEvoy, JP, et al. (2005) Effectiveness of antipsychotic drugs in patients with schizophrenia. New England Journal of Medicine, 353: 1209–23.
Lim, SAO, Kang, UJ, McGehee, DS (2014) Striatal cholinergic interneuron regulation and circuit effects. Frontiers in Synaptic Neuroscience, 6: 1–23.
Lister, J, Nobrega, JN, Fletcher, PJ (2014) Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence from antioxidant-based prevention strategies. Psychopharmacology, 231: 2237–49.
Lister, J, Andreazza, AC, Navaid, B, et al. (2017) Lipoic acid and haloperidol-induced vacuous chewing movements: implications for prophylactic antioxidant use in tardive dyskinesia. Progress in Neuropsychopharmacology and Biological Psychiatry, 72: 23–9.
Lohr, JB (1991) Oxygen radicals and neuropsychiatric illness: some speculations. Archives of General Psychiatry, 48: 1097–106.
Louza, MR, Bassitt, DP (2005) Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years’ follow-up. Journal of Clinical Psychopharmacology, 25: 180–2.
Miller, R, Chouinard, G (1993) Loss of striatal cholinergic neurones as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry, 34: 713–38.
O'Brien, CF, Jiminez, R, Hauser, RA, et al. (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Movement Disorders, 30: 1681–7.
Owens, DGC, Finlayson, A, Mercer, G, et al. (1997) The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophrenia. Journal of Psychopharmacology, 11: 357–60.
Owens, DGC (2014) A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs (2nd edn). Cambridge University Press.
Owens, DGC (2018) Tardive dyskinesia: an update. 1. The syndrome. BJPsych Advances, 25: 57–69.
Pouclet-Courtemanche, H, Rouand, T, Thobois, S, et al. (2016) Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology, 86: 651–9.
Rodrigues, FB, Duarte, GS, Costa, J, et al. (2017) Meta-research metrics matter: letter regarding article ‘indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. Journal of Clinical Movement Disorders, 4: 19.
Shi, J, Tan, YL, Wang, ZR, et al. (2016) Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewing movement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. Pharmacology, Biochemistry and Behaviour, 148: 53–8.
Soares-Weiser, K, Maayan, N, McGrath, J (2011) Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, 2: CD000209 (doi: 10.1002/14651858.CD000209.pub.2).
Sun, CH, Zheng, W, Yang, XH, et al. (2017) Adjunctive melatonin for tardive dyskinesia in patients with schizophrenia: a meta-analysis. Shanghai Archives of Psychiatry, 29: 129–36.
Tammenmaa-Aho, I, Asher, R, Soares-Weiser, K, et al. (2018) Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, 3: CD000207 (doi: 10.1002/14651858.CD000207.pub2).
Teo, JT, Edwards, MJ, Bhatia, K (2012) Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Movement Disorders, 27: 1205–15.
Thaakur, S, Himabindhu, G (2009) Effect of alpha lipoic acid on tardive dyskinesia and oxidative stress induced by haloperidol in rats. Journal of Neural Transmission, 116: 807–14.
Thaker, GK, Nguyen, JA, Strauss, ME, et al. (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. American Journal of Psychiatry, 147: 445–51.
Verdoux, H, Tournier, M, Begaud, B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatrica Scandinavica, 121: 4–10.
Waddington, J (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology, 101: 431–7.
Zhang, WF, Tan, YL, Zhang, XY, et al. (2011) Extract of Gingko Biloba treatment for tardive dyskinesia in schizophrenia: a randomised, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 72: 615–21.